title: [Levofloxacin and other fluoroquinolones in therapy of respiratory tract infections].
abstract: Levofloxacin, like other fluoroquinolones, acts as a antibacterial agent on bacterial topoisomerases. A broad range of Gram-positive and Gram-negative of levofloxacin was confirmed in clinical trials in patients with respiratory tract infections. In therapy of chronic diseases exacerbations of the respiratory tract, including community-acquired pneumonia, a high oral bioavailability allows to switch from intravenous to oral way of treatment. Although a high penetration degree of levofloxacin into serum and tissues gives possibility to control bacterial biofilm. For this reasons levofloxacin is recommended for therapy of respiratory tract infections as a second-line antibacterial agent, but in severe exacerbations may be considered as additional therapy, rarely as monotherapy.
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Płusa
mesh_terms: D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001682:Biological Availability; D024841:Fluoroquinolones / Q000627:therapeutic use; D006801:Humans; D064704:Levofloxacin; D015242:Ofloxacin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D064704:Levofloxacin; D015242:Ofloxacin